Radnor Capital Management LLC Takes $903,000 Position in ResMed Inc. (NYSE:RMD)

Radnor Capital Management LLC acquired a new stake in shares of ResMed Inc. (NYSE:RMD - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,700 shares of the medical equipment provider's stock, valued at approximately $903,000.

A number of other hedge funds also recently bought and sold shares of RMD. Pittenger & Anderson Inc. grew its holdings in shares of ResMed by 9.4% during the 3rd quarter. Pittenger & Anderson Inc. now owns 58,324 shares of the medical equipment provider's stock valued at $14,238,000 after purchasing an additional 5,034 shares during the last quarter. QRG Capital Management Inc. boosted its position in ResMed by 426.5% during the third quarter. QRG Capital Management Inc. now owns 6,797 shares of the medical equipment provider's stock valued at $1,659,000 after buying an additional 5,506 shares during the period. Asset Management One Co. Ltd. grew its stake in shares of ResMed by 5.1% during the third quarter. Asset Management One Co. Ltd. now owns 58,860 shares of the medical equipment provider's stock valued at $14,369,000 after buying an additional 2,878 shares during the last quarter. National Pension Service increased its holdings in shares of ResMed by 5.0% in the third quarter. National Pension Service now owns 227,655 shares of the medical equipment provider's stock worth $55,575,000 after buying an additional 10,880 shares during the period. Finally, Angeles Wealth Management LLC bought a new stake in shares of ResMed in the 3rd quarter valued at about $274,000. Institutional investors own 54.98% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on RMD shares. Wolfe Research restated an "underperform" rating and set a $180.00 price target on shares of ResMed in a research report on Wednesday, September 18th. Baird R W upgraded shares of ResMed to a "strong-buy" rating in a report on Tuesday, September 24th. KeyCorp lifted their target price on shares of ResMed from $251.00 to $266.00 and gave the stock an "overweight" rating in a research note on Friday, October 25th. Robert W. Baird raised their price target on shares of ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Finally, StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ResMed presently has a consensus rating of "Moderate Buy" and an average target price of $225.70.

Insider Activity

In related news, insider Kaushik Ghoshal sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the completion of the transaction, the insider now owns 21,788 shares of the company's stock, valued at $5,502,777.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Kaushik Ghoshal sold 5,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the sale, the insider now directly owns 21,788 shares of the company's stock, valued at approximately $5,502,777.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brett Sandercock sold 1,000 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $246.42, for a total transaction of $246,420.00. Following the sale, the chief financial officer now owns 96,812 shares of the company's stock, valued at approximately $23,856,413.04. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,260 shares of company stock worth $14,390,487. Insiders own 0.71% of the company's stock.

ResMed Stock Up 1.4 %

Shares of RMD stock traded up $3.31 during midday trading on Thursday, reaching $248.42. 815,806 shares of the stock were exchanged, compared to its average volume of 1,051,547. The company's 50 day moving average is $243.12 and its two-hundred day moving average is $221.39. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. The firm has a market cap of $36.47 billion, a PE ratio of 32.92, a price-to-earnings-growth ratio of 1.78 and a beta of 0.69. ResMed Inc. has a 1 year low of $140.81 and a 1 year high of $260.49.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts' consensus estimates of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the prior year, the firm earned $1.64 EPS. The company's revenue was up 11.1% compared to the same quarter last year. On average, equities research analysts predict that ResMed Inc. will post 9.22 EPS for the current year.

ResMed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $2.12 annualized dividend and a dividend yield of 0.85%. ResMed's payout ratio is 28.08%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.